613256-52-3 Usage
Description
1-[(2R)-3-Hydroxy-2-Methyl-1-oxopropyl]-L-proline is a chiral compound that features a unique structure with a hydroxyl and a methyl group attached to a proline backbone. This organic compound is characterized by its specific stereochemistry, with the R-configuration at the second carbon, which is crucial for its reactivity and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
1-[(2R)-3-Hydroxy-2-Methyl-1-oxopropyl]-L-proline serves as a key intermediate in the synthesis of the antihypertensive drug Captopril (C175750). Its unique structure and stereochemistry play a vital role in the development of this medication, which is utilized for treating high blood pressure and preventing organ damage associated with hypertension.
In the synthesis of Captopril, 1-[(2R)-3-Hydroxy-2-Methyl-1-oxopropyl]-L-proline is used as a building block to construct the final drug molecule. The specific R-configuration at the second carbon ensures that the resulting Captopril has the desired biological activity and efficacy in managing blood pressure levels. This application highlights the importance of chiral compounds in the pharmaceutical industry, where the stereochemistry of a molecule can significantly impact its therapeutic properties.
Check Digit Verification of cas no
The CAS Registry Mumber 613256-52-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,3,2,5 and 6 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 613256-52:
(8*6)+(7*1)+(6*3)+(5*2)+(4*5)+(3*6)+(2*5)+(1*2)=133
133 % 10 = 3
So 613256-52-3 is a valid CAS Registry Number.
613256-52-3Relevant articles and documents
A DRUG AND SYNTHESIS OF THE DRUG TO TREAT HIGH BLOOD PRESSURE AND TYPE 2 DIABETES MELLITUS DISEASE
-
Page/Page column 12; 13, (2022/02/28)
The invention relates to a drug and its method of manufacture, which allows to reduce hypertension and treat type 2 diabetes mellitus by using the drug as a dipeptidyl peptidase-4 (DPP-4) inhibitor. The rate of hypoglycemia of the drug in question is low and provides glycemic control and weight loss. The method of manufacturing the mentioned drug includes practical steps to convert the carboxyl group from captopril (1) to the nitrile group.